These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro effects of urokinase--prevention by different inhibitors.
    Author: Oethinger MD, Seifried E.
    Journal: Thromb Haemost; 1990 Nov 30; 64(3):402-6. PubMed ID: 1710833.
    Abstract:
    The present in vitro study investigated dose-, time- and temperature-dependent effects of two-chain urokinase plasminogen activator (u-PA, urokinase) on normal citrated plasma. When 10 micrograms/ml u-PA were added to pooled normal plasma and incubated for 30 min at an ambient temperature (25 degrees C), alpha 2-antiplasmin decreased to 8% of the control value. Incubation on ice yielded a decrease to 45% of control, whereas alpha 2-antiplasmin was fully consumed at 37 degrees C. Fibrinogen and plasminogen fell to 46% and 39%, respectively, after a 30 min incubation at 25 degrees C. Thrombin time prolonged to 190% of control. Various inhibitors were studied with respect to their suitability and efficacy to prevent these in vitro effects. Aprotinin exhibited a good protective effect on fibrinogen at concentrations exceeding 500 KIU/ml plasma. Its use, however, was limited due to interferences with some haemostatic assays. We could demonstrate that L-Glutamyl-L-Glycyl-L-Arginyl chloromethyl ketone (GGACK) and a specific polyclonal anti-u-PA-antibody (anti-u-PA-IgG) effectively inhibited urokinase-induced plasmin generation without interfering with haemostatic assays. The anti-u-PA-antibody afforded full protection of alpha 2-antiplasmin at therapeutic levels of u-PA. It is concluded that u-PA in plasma samples from patients during thrombolytic therapy may induce in vitro effects which should be prevented by the use of a suitable inhibitor such as GGACK or specific anti-u-PA-antibody.
    [Abstract] [Full Text] [Related] [New Search]